NEW YORK (GenomeWeb News) – Clinical research organization Covance said after the close of the market on Wednesday that it will acquire Merck's Seattle-based gene expression laboratory.

Although the Princeton, NJ-based firm did not disclose the price of the acquisition, it said that Merck had committed to a five-year genomic analysis services contract worth $145 million as part of the deal. The lab performs genotyping, gene sequencing, and gene expression profiling services. The firms did not provide revenue figures for the lab.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.